Tau-pS413 Antibodies via Variable Region Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-tau antibodies lack high affinity for pathological tau species, such as tau-pS413, leading to ineffective treatment of tauopathies due to low specificity and the need for high dosages to achieve therapeutic levels in the brain, where the blood-brain barrier restricts antibody migration.
Innovation Solution
Development of high affinity antibodies or antigen binding fragments that specifically target tau-pS413, comprising optimized heavy and light chain variable regions with specific amino acid sequences, which enhance binding potency and prevent tau pathology in neuronal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-tau antibodies are used, then they can bind to tau protein, but they lack high affinity for pathological tau species (tau-pS413) and have low specificity
Solution Approach 1:
The patent applies parameter changes by optimizing the amino acid sequences in the variable regions of the antibody (particularly CDR3 of heavy chain and CDR1 of light chain) to achieve high affinity binding to tau-pS413. This molecular-level parameter optimization enables the antibody to specifically recognize pathological tau species without requiring high dosages.
Solution Approach 2:
The patent employs local quality by designing antibodies with specific amino acid substitutions in localized regions (variable domains, especially CDRs) that confer high affinity and specificity for tau-pS413, while the rest of the antibody structure remains standard. This localized optimization achieves the desired binding properties without modifying the entire antibody molecule.
2Reliability
If high dosages of antibodies are administered to achieve therapeutic levels in the brain, then effective treatment may be reached, but the blood-brain barrier restricts antibody migration making this approach problematic
Solution Approach 1:
By optimizing the binding affinity parameters of the antibody through amino acid sequence optimization, the patent achieves high therapeutic effectiveness at lower dosages. This reduces the burden on blood-brain barrier transport and minimizes the harmful effects of high-dose administration while still achieving effective concentrations in the brain.
3Quantity of substance
If antibodies with low specificity are used, then they can bind to both pathological and normal tau, but this leads to ineffective treatment due to inability to distinguish pathological tau species
Solution Approach 1:
The patent applies local quality by introducing specific amino acid substitutions in the variable regions (particularly CDR3 of heavy chain and CDR1 of light chain) that create a binding interface specifically recognizing the phosphorylated serine 413 epitope on pathological tau. This localized modification enables the antibody to distinguish pathological tau species from normal tau while maintaining appropriate binding breadth.
Solution Approach 2:
The patent uses parameter changes by optimizing the binding affinity and specificity parameters through amino acid sequence optimization in the variable regions. This enables the antibody to achieve high discrimination between pathological and normal tau species while maintaining sufficient binding breadth for effective treatment.
Data Source
AI summary
Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.